Leerink raised the firm’s price target on Revvity to $135 from $130 and keeps an Outperform rating on the shares ahead of Q3 earnings, as the firm previews key debates for companies across its Life Science Tools and Diagnostics coverage. Leerink sees three major themes, namely the timing of recovery in core pharma/biotech end-markets, China still weak but stable sequentially, and possible weakness in academic end-market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Big banks, UnitedHealth report quarterly earnings: Morning Buzz
- Etsy, Enphase downgraded: Wall Street’s top analyst calls
- Barclays upgrades Revvity, says stock ‘checks most of the boxes’
- Revvity upgraded to Overweight from Equal Weight at Barclays
- Wells Fargo initiates Revvity with an Equal Weight, $130 price target